SCHEMBL989220

SCHEMBL989220

CC(C)Cn1c(N)nc2ccc(-c3cn(C(c4ccccc4)(c4ccccc4)c4ccccc4)nc3-c3ccc(F)cc3F)cc21

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKD3 O94806 4/20 0.47
MAP4K4 O95819 4/20 0.47
MAPK9 P45984 4/20 0.47
CSNK1D P48730 4/20 0.47
MINK1 Q8N4C8 4/20 0.47
PRKD2 Q9BZL6 4/20 0.47
ERBB2 P04626 3/20 0.47
MAPK8 P45983 3/20 0.47
MAP4K2 Q12851 3/20 0.47
CAMK2B Q13554 3/20 0.47
DYRK1A Q13627 3/20 0.47
ERBB4 Q15303 3/20 0.47
FGFR1 P11362 3/20 0.47
MAP4K5 Q9Y4K4 3/20 0.47
PIM1 P11309 2/20 0.47
CAMK2G Q13555 2/20 0.47
PIM3 Q86V86 2/20 0.47
MKNK2 Q9HBH9 2/20 0.47
LIMK1 P53667 2/20 0.47
TAOK1 Q7L7X3 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5985084 0.78 PRKD3 (0.50) PRKD3MAP4K4MAPK9CSNK1DMINK1
SCHEMBL989434 0.73 MAPK14 (0.54) PRKD3MAP4K4MAPK9CSNK1DMINK1
SCHEMBL3845874 0.71 CDK9 (0.34) FGFR1
SCHEMBL989284 0.70 MAPK14 (0.51) PRKD3MAP4K4MAPK9CSNK1DMINK1
SCHEMBL991919 0.69 MAPK14 (0.51) PRKD3MAP4K4MAPK9CSNK1DMINK1
SCHEMBL3846760 0.68 PDE7A (0.36) CSNK1DCLK4MAPK14CYP1A2CYP2D6
SCHEMBL989421 0.68 ADORA1 (0.36) MAPK14ADORA2AADORA1
SCHEMBL989440 0.68 MAPK14 (0.55) PRKD3MAP4K4MAPK9CSNK1DMINK1
SCHEMBL3855063 0.67 CYP1A2 (0.38) CLK4MAPK14CYP1A2CYP2D6CYP2C19
SCHEMBL3845533 0.67 TP53 (0.36) PRKD3MAP4K4MAPK9CSNK1DPRKD2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7863310-B2 Kinase inhibitors ELI LILLY AND COMPANY (US) 2011-01-04 US disclosed
US-20080227839-A1 Kinase Inhibitors ELI LILLY AND COMPANY 2008-09-18 US disclosed
EP-1720862-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2006-11-15 EP disclosed
WO-2005080380-A1 KINASE INHIBITORS ELI LILLY AND COMPANY (US) 2005-09-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227839-A1 Kinase Inhibitors ABL1, MAP3K20, MAP3K19 PRKD3 213/4885MAP4K4 64/4885MAPK9 140/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.